Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …

Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest malignancies,
with dismal survival rates and extremely prevalent chemoresistance. Gemcitabine is one of …

Pancreatic ductal adenocarcinoma (PDAC) is among the most devastating human
malignancies. The poor clinical outcome in PDAC is partly attributed to a growth-permissive …

Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths. The
disappointing 5-year survival rate of below 5% stems from drug resistance to all known …

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant
cancers, and current therapies targeting cancer-associated molecular pathways have not …

A high number of cancer patients around the world rely on gemcitabine (GEM) for
chemotherapy. During local metastasis of cancers, surgery is beneficial for therapy, but …

Pancreatic cancer is one of the most lethal types of cancer in the world. The incidence of
pancreatic cancer increases each year with no significant decrease in mortality. Pancreatic …

Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide.
Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma …

Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer,
ranks among the leading causes of cancer-related deaths in the Western world due to …

Pancreatic ductal adenocarcinoma, an exocrine tumor, is the most common type of cancer of
the pancreas and one of the top five most prominent causes of cancer-associated mortality …